UBS Group AG grew its holdings in Allakos Inc (NASDAQ:ALLK) by 182.6% in the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 1,088 shares of the company’s stock after buying an additional 703 shares during the quarter. UBS Group AG’s holdings in Allakos were worth $78,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also bought and sold shares of the company. Mackay Shields LLC grew its holdings in shares of Allakos by 13.9% during the second quarter. Mackay Shields LLC now owns 18,000 shares of the company’s stock valued at $1,294,000 after purchasing an additional 2,200 shares during the last quarter. Zurcher Kantonalbank Zurich Cantonalbank increased its stake in shares of Allakos by 39.8% in the second quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 2,015 shares of the company’s stock worth $145,000 after purchasing an additional 574 shares in the last quarter. Dupont Capital Management Corp purchased a new position in shares of Allakos in the second quarter worth about $265,000. Candriam Luxembourg S.C.A. increased its stake in shares of Allakos by 123.7% in the second quarter. Candriam Luxembourg S.C.A. now owns 111,872 shares of the company’s stock worth $8,039,000 after purchasing an additional 61,872 shares in the last quarter. Finally, Strs Ohio purchased a new position in shares of Allakos in the second quarter worth about $35,000. 71.49% of the stock is owned by institutional investors and hedge funds.

Shares of NASDAQ:ALLK opened at $80.87 on Thursday. Allakos Inc has a 12-month low of $41.60 and a 12-month high of $139.99. The company has a market capitalization of $3.96 billion, a PE ratio of -34.41 and a beta of 1.01. The business has a 50 day moving average of $84.40 and a two-hundred day moving average of $70.56.

Allakos (NASDAQ:ALLK) last announced its earnings results on Monday, August 10th. The company reported ($0.80) earnings per share for the quarter, missing the consensus estimate of ($0.61) by ($0.19). On average, equities research analysts anticipate that Allakos Inc will post -3.1 EPS for the current year.

A number of brokerages have recently weighed in on ALLK. BidaskClub upgraded shares of Allakos from a “hold” rating to a “buy” rating in a report on Saturday, August 15th. Zacks Investment Research downgraded shares of Allakos from a “hold” rating to a “sell” rating in a research report on Friday, August 14th. Two investment analysts have rated the stock with a sell rating, two have given a hold rating and two have assigned a buy rating to the stock. The stock currently has a consensus rating of “Hold” and a consensus price target of $67.67.

Allakos Company Profile

Allakos Inc, a clinical stage biopharmaceutical company, focuses on developing therapeutic antibodies targeting allergic, inflammatory, and proliferative diseases. The company is developing AK002 for the treatment of eosinophilic gastritis and eosinophilic gastroenteritis, urticaria, indolent systemic mastocytosis, and severe allergic conjunctivitis.

Read More: Equity Income

Institutional Ownership by Quarter for Allakos (NASDAQ:ALLK)

Receive News & Ratings for Allakos Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allakos and related companies with MarketBeat.com's FREE daily email newsletter.